{
    "title": "FDA decision on Eisai, Biogen Alzheimer's drug due in January",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10985769/FDA-decision-Eisai-Biogen-Alzheimers-drug-January.html",
    "date": "2022-07-05",
    "keywords": [
        "drug",
        "trial",
        "lecanemab",
        "aduhelm",
        "year",
        "eisai",
        "approval",
        "march",
        "fda",
        "beasley",
        "biogen",
        "decline",
        "impact",
        "phase",
        "study",
        "application",
        "july",
        "food",
        "administration",
        "review",
        "co",
        "ltds",
        "decision",
        "jan",
        "antibody",
        "protein",
        "beta",
        "disease",
        "loss",
        "inability",
        "june",
        "latestage",
        "panel",
        "price",
        "government",
        "health",
        "plan",
        "age",
        "role",
        "leader",
        "program",
        "fdas",
        "cognition",
        "biomarker",
        "level",
        "brain",
        "standard",
        "efficacy",
        "fall",
        "question",
        "ability",
        "rate",
        "cognitive",
        "coverage",
        "cheung",
        "chairman",
        "september",
        "confirmatory",
        "benefit",
        "end",
        "company",
        "agency",
        "time",
        "period",
        "europe",
        "reporting",
        "deena",
        "sam"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}